Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hunt

Showing results (641-650 of 671) with videos related to

Pageof 68
Sort By:
Journal of Proteome Research|January 26, 2010
Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometryCloud P Paweletz, Matthew C Wiener, Andrey Y Bondarenko, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2008
Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitorRéjean Ruel, Carl Thibeault, Alexandre L'Heureux, et al.
Journal of Medicinal Chemistry|December 22, 1999
Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferaseC Z Ding, R Batorsky, R Bhide, et al.
Journal of Medicinal Chemistry|December 22, 1999
Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferaseC Z Ding, R Batorsky, R Bhide, et al.
Journal of Medicinal Chemistry|October 6, 2000
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activityJ T Hunt, C Z Ding, R Batorsky, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinaseGretchen M Schroeder, Xiao-Tao Chen, David K Williams, et al.
Journal of Medicinal Chemistry|December 19, 1998
Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308)N Murugesan, Z Gu, P D Stein, et al.
Human Molecular Genetics|July 1, 2005
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutationsP J Pollard, J J Brière, N A Alam, et al.
The Lancet. Infectious Diseases|July 20, 2023
Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational studyHallie Cohn, Nathaniel Bloom, Gianna Y Cai, et al.
Cell Reports. Medicine|June 21, 2021
Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severityJennifer L Yates, Dylan J Ehrbar, Danielle T Hunt, et al.
Pageof 68

Showing results (641-650 of 671) with videos related to

Sort By:
Pageof 68
Journal of Proteome Research|January 26, 2010
Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometryCloud P Paweletz, Matthew C Wiener, Andrey Y Bondarenko, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2008
Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitorRéjean Ruel, Carl Thibeault, Alexandre L'Heureux, et al.
Journal of Medicinal Chemistry|December 22, 1999
Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferaseC Z Ding, R Batorsky, R Bhide, et al.
Journal of Medicinal Chemistry|December 22, 1999
Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferaseC Z Ding, R Batorsky, R Bhide, et al.
Journal of Medicinal Chemistry|October 6, 2000
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activityJ T Hunt, C Z Ding, R Batorsky, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinaseGretchen M Schroeder, Xiao-Tao Chen, David K Williams, et al.
Journal of Medicinal Chemistry|December 19, 1998
Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308)N Murugesan, Z Gu, P D Stein, et al.
Human Molecular Genetics|July 1, 2005
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutationsP J Pollard, J J Brière, N A Alam, et al.
The Lancet. Infectious Diseases|July 20, 2023
Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational studyHallie Cohn, Nathaniel Bloom, Gianna Y Cai, et al.
Cell Reports. Medicine|June 21, 2021
Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severityJennifer L Yates, Dylan J Ehrbar, Danielle T Hunt, et al.
Pageof 68